ADMA Biologics, Inc.

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

Groundbreaking Immunotechnology, One Connection at a Time.

ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing, and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart.

View Our Latest Corporate Presentation
Secondary Image

Discover ADMA Biologics' Patented Immunotechnology*

Designed for the immunocompromised

We manufacture, develop, and commercialize specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised at risk for certain infections.

Screen and identify high-titer donors:


Hyperimmune donors with high-titer antibodies to select pathogens are identified.

Tailored compositions:


Tailored plasma pools are derived from a unique blend of normal source plasma and plasma obtained from the selected donors.

Proprietary testing:


A proprietary microneutralization assay quantitatively measures titer levels of neutralizing RSV antibodies in plasma donor samples.

Learn more about ADMA Biologics

*The following patents are applied to ASCENIV™ (immune globulin intravenous, human – slra): 9,107,906 composition 9,714,283 use 9,815,886 methods expiration 2035

Fiscal Year 2022 Report Cover Download Fiscal Year 2022 Report
Investor Relations

Our Diversity Makes Us Stronger

The members of ADMA Biologics' management team come from different disciplines and professional backgrounds. We share a common passion and desire to drive goals that improve the lives of patients.

Meet the ADMA Team

Latest News & Alerts

View All News & Alerts